Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01255462 · ClinicalTrials.gov registry record · Phase 1
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01255462 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT01255462, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.
Interventions
- BIOLOGICAL LFG316
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01255462
The ClinicalTrials.gov registry entry for NCT01255462 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LFG316 is the first listed.
NCT01255462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01255462 about?
NCT01255462 is a clinical study titled "Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration". This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.
What is the current status of trial NCT01255462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-11. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01255462?
The interventions under investigation include: LFG316 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01255462?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.